Retatrutide, a experimental dual agonist of the GLP-1 binding site and glucose-dependent insulinotropic polypeptide (GIP) binding site , is showing promising results in early clinical studies. Recent https://bookmarkhard.com/story21378513/retatrutide-emerging-research-and-potential-therapeutic-roles